Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection
Abstract
The pathogenesis of Ebola virus disease (EVD) in humans is complex, and the mechanisms contributing to immunity are poorly understood. In particular, it appears that the quality and magnitude of the human B cell response early after recovery from EVD may be reduced compared to most viral infections. Here, we isolated human monoclonal antibodies from B cells of four survivors of EVD at 1 or 3 months after hospital discharge. Ebola-specific memory B cells early in convalescence were low in frequency, and the antibodies they encoded demonstrated poor neutralizing potencies. One neutralizing antibody that protected mice from lethal infection, EBOV237, was identified in the panel of 25 human antibodies isolated. Recognition of the glycan cap epitope recognized by EBOV237 suggests that this antigenic site should be considered in vaccine design and treatment strategies for EVD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 15, 2019
- Source ID
- 10.1128/jvi.01439-18
Entities
People
- Andre Branchizio
- Andrew I. Flyak
- Ashley E Piper
- Benjamin J Doranz
- Edgar Davidson
- Erica Ollmann Saphire
- James E. Crowe, Jr.
- Lauren E Williamson
- Marnie L. Fusco
- Nurgun Kose
- Pamela J Glass
- Peter J Halfmann
- Robin Bombardi
- Srikar Reddy
- Yoshihiro Kawaoka
Organizations
- California Institute of Technology
- Defense Threat Reduction Agency
- Integral Molecular
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- Scripps Research
- United States Army Medical Research Institute of Infectious Diseases
- University of Wisconsin–Madison
- Vanderbilt University